The continuing clinical use of (S)NRIs to treat anxiety and depression as well as the recent developments of NET inhibitors as potential treatment for incontinence11, excessive sleepiness12 and neuropathic pain13,14 still warrant the discovery of novel NET inhibitors. This evidence concerns the gene SLC6A2 and major depressive disorder.